aTyr Pharma to Present at Upcoming Investor Conferences in May

Rhea-AI Summary

SAN DIEGO, May 10, 2022 – aTyr Pharma (Nasdaq: LIFE) announced its participation in two investor conferences in May.

Details include:

• RBC Capital Markets Global Healthcare Conference: May 18, 2022, at 10:30 a.m. EDT, New York, NY, featuring CEO Sanjay S. Shukla in a fireside chat.
• H.C. Wainwright Global Investment Conference: May 24, 2022, at 4:30 p.m. EDT, Miami, FL, with Ashlee Dunston, Director of Investor Relations, presenting.

Management will also engage in one-on-one investor meetings. Presentations will be available for replay on the company's website.

SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA synthetase biology platform, today announced that the company will present at two upcoming investor conferences in May.

Details of the events are as follows:

Conference: 2022 RBC Capital Markets Global Healthcare Conference
Date: May 18, 2022
Time: 10:30 a.m. EDT
Location: New York, NY
Presenter: Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer
Format: Fireside Chat

Conference: H.C. Wainwright Global Investment Conference
Date: May 24, 2022
Time: 4:30 p.m. EDT
Location: Miami, FL
Presenter: Ashlee Dunston, Director, Investor Relations and Corporate Communications
Format: Corporate Presentation

In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conferences. Following the events, a replay of each presentation will be available on the Investor’s section of the company’s website at www.atyrpharma.com.

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA synthetase biology platform. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.

Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com

FAQ

What conferences will aTyr Pharma present at in May 2022?

aTyr Pharma will present at the RBC Capital Markets Global Healthcare Conference on May 18 and the H.C. Wainwright Global Investment Conference on May 24.

Who will represent aTyr Pharma at the RBC Capital Markets Conference?

Sanjay S. Shukla, M.D., M.S., President and CEO, will represent aTyr Pharma at the RBC Capital Markets Global Healthcare Conference.

What is the date and time of aTyr Pharma's presentation at the H.C. Wainwright Global Investment Conference?

aTyr Pharma's presentation at the H.C. Wainwright Global Investment Conference is scheduled for May 24, 2022, at 4:30 p.m. EDT.

Will aTyr Pharma's presentations be available for later viewing?

Yes, replays of each presentation will be available on aTyr Pharma's Investor section of their website after the events.

What is aTyr Pharma's focus area in biotherapeutics?

aTyr Pharma focuses on innovative medicines based on tRNA synthetase biology, with a primary focus on efzofitimod for inflammatory lung diseases.